NASDAQ:PYXS

Pyxis Oncology Stock Insider Trading

etoro logo Buy PYXS
*Your capital is at risk
$2.44
-0.230 (-8.61%)
At Close: Jul 13, 2026

Pyxis Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.61. In total, the insiders bought 19.36M and sold 124.39K PYXS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
94.61
Buy 19.36M shares
Sell 124.39K shares
94% Buy Activity
Moderate Negative Correlation
Sell Signal Low Confidence
Jun 30, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 94.61.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 30, 2026
Buy
Common Stock Purchase Warrant
Gordonmd Global Investments Lp
10 Percent Owner
10% Owner 4 900 039
Value: $16.1M
Jun 30, 2026
Buy
Common Stock, par value $0.001 per share
Gordonmd Global Investments Lp
10 Percent Owner
10% Owner 0
Value: $0
Jun 30, 2026
Sell
Common Stock
S-Sale
Dupont Jakob
Director
Director 35 000
Value: $107.1K
Jun 30, 2026
Buy
Common Stock
M-Exempt
Dupont Jakob
Director
Director 35 000
Value: $56.0K
Jun 30, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Dupont Jakob
Director
Director 35 000
Value: $56.0K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Palani Santhosh
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Humphrey Rachel
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Cline Darren S
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Lewis-hall Freda C
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Metzger Michael A
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Flavin John L
Director
Director 45 867
Value: $62.4K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Wadhane Jitendra
Prin Fin & Acct Officer
Officer 262 635
Value: $357.2K
Mar 24, 2026
Buy
Common Stock
A-Award
Wadhane Jitendra
Prin Fin & Acct Officer
Officer 109 461
Value: $148.9K
Mar 24, 2026
Buy
Stock Option (Right to Buy)
A-Award
Dupont Jakob
Director
Director 45 867
Value: $62.4K
Feb 03, 2026
Buy
Stock Option (Right to Buy)
A-Award
Civik Thomas
Interim CEO
CEO / President 690 131
Value: $1.03M
Apr 21, 2025
Sell
Common Stock
S-Sale
Humphrey Rachel
Director
Director 13 896
Value: $14.4K
Apr 17, 2025
Sell
Common Stock
S-Sale
Humphrey Rachel
Director
Director 200
Value: $194
Apr 14, 2025
Sell
Common Stock
S-Sale
Humphrey Rachel
Director
Director 1 400
Value: $1K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Sullivan Lara
President ,ceo & Cmo
CEO / President 918 308
Value: $899.9K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Metzger Michael A
Director
Director 36 979
Value: $36.2K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Wadhane Jitendra
SVP, Chief Accounting Officer
Officer 263 782
Value: $258.5K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Humphrey Rachel
Director
Director 36 979
Value: $36.2K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Lewis-hall Freda C
Director
Director 36 979
Value: $36.2K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Cline Darren S
Director
Director 36 979
Value: $36.2K
Mar 31, 2025
Buy
Stock Option (Right to Buy)
A-Award
Dupont Jakob
Director
Director 36 979
Value: $36.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT PYXIS ONCOLOGY, INC.
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
10.58% Jun 29
NMRK
$15.02
0.466% Jun 24
X
XMAX
$8.34
2.40% Jun 24
NESR
$25.07
12.49% Jun 23
CAG
$13.43
6.70% Jun 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE